In vitro cytotoxicity on human ovarian cancer cells by T-type calcium channel blockers

Bioorganic and Medicinal Chemistry Letters

Volumn 23, Issue 24, 2013, Pages 6656-6662

  Jang, Sun Jeong ^a   Choi, Heung Woo ^a   Choi, Doo Li ^a   Cho, Sehyeon ^a   Rim, Hong Kun ^a   Choi, Hye Eun ^a   Kim, Ki Sun ^b   Huang, Minghua ^c,d   Rhim, Hyewhon ^c,d   Lee, Kyung Tae ^a   Lee, Jae Yeol ^a  

^a Kyung Hee University   (South Korea)

^b Sehan University   (South Korea)

^c Korea Institute of Science and Technology   (South Korea)

^d University of Science and Technology (UST)   (South Korea)

Author keywords

Apoptosis; Cell cycle arrest; Cytotoxicity; Ovarian cancer; T type Ca2+ channel

Indexed keywords

3,4 QUINAZOLINEDIOL DERIVATIVE; ANTINEOPLASTIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL T TYPE; KYS 05090; MIBEFRADIL; PACLITAXEL; UNCLASSIFIED DRUG;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CONTROLLED STUDY; CYTOTOXICITY; DRUG STRUCTURE; DRUG SYNTHESIS; FEMALE; FLOW CYTOMETRY; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; HYDROPHOBICITY; IN VITRO STUDY; OVARY CARCINOMA; STRUCTURE ACTIVITY RELATION;

APOPTOSIS; CELL CYCLE ARREST; CYTOTOXICITY; OVARIAN CANCER; T-TYPE CA(2+) CHANNEL;

CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS, T-TYPE; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL SURVIVAL; FEMALE; HUMANS; OVARIAN NEOPLASMS; QUINAZOLINES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84888875574     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2013.10.049     Document Type: Article

References (34)

1. K. Miyazaki, K. Shimada, H. Katabuchi, F. Arakane, S. Arao, and H. Okamura Gynecol. Oncol. 58 1995 362
2. http://www.cancer.gov/cancertopics/types/ovarian.
3. M.J. Berridge, P. Lipp, and M.D. Bootman Nat. Rev. Mol. Cell Biol. 1 2000 11
4. M.J. Berridge, M.D. Bootman, and H.L. Roderick Nat. Rev. Mol. Cell Biol. 4 2003 517
5. J.F. Whitfield, A.L. Boynton, J.P. MacManus, R.H. Rixon, M. Sikorska, B. Tsang, P.R. Walker, and S.H. Swierenga Ann. N.Y. Acad. Sci. 339 1980 216
6. F. Moolenaar, J.P. Yska, J. Visser, and D.K. Meijer Eur. J. Clin. Pharmacol. 29 1985 119
7. M. Whitaker, and R. Patel Development 108 1990 525
8. K.P. Lu, and A.R. Means Endocr. Rev. 14 1993 40
9. D.E. Clapham Cell 80 1995 259
10. L.S. Gray, E. Perez-Reyes, J.C. Gamorra, D.M. Haverstick, M. Shattock, L. McLatchie, J. Harper, G. Brooks, T. Heady, and T.L. Macdonald Cell Calcium 36 2004 489
11. E. Perez-Reyes, and P. Lory CNS Neurol. Disord. Drug Targets 5 2006 605
12. L.L. Cribbs, J.H. Lee, J. Yang, J. Satin, Y. Zhang, A. Daud, J. Barclay, M.P. Williamson, M. Fox, M. Rees, and E. Perez-Reyes Circ. Res. 83 1998 103
13. A. Monteil, J. Chemin, E. Bourinet, G. Mennessier, P. Lory, and J. Nargeot J. Biol. Chem. 275 2000 6090
14. A. Monteil, J. Chemin, V. Leuranguer, C. Altier, G. Mennessier, E. Bourinet, P. Lory, and J. Nargeot J. Biol. Chem. 275 2000 16530
15. P. Lory, I. Bidaud, and J. Chemin Cell Calcium 40 2006 135
16. M.J. Berridge Neuron 21 1988 13
17. A.M. Yunker, and M.W. McEnery J. Bioenerg. Biomembr. 35 2003 533
18. J. Chemin, A. Monteil, and P. Lory J. Soc. Biol. 197 2003 235
19. E. Perez-Reyes Physiol. Rev. 83 2003 117
20. M. Li, and Z.-G. Xiong Int. J. Physiol. Pathophysiol. Pharmacol. 3 2011 156
21. I. Latour, D.F. Louw, A.M. Beedle, J. Hamid, G.R. Sutherland, and G.W. Zamponi Glia 48 2004 112
22. J.T. Taylor, X.-B. Zeng, J.E. Pottle, K. Lee, A.R. Wang, S.G. Yi, J.A. Scruggs, S.S. Sikka, and M. Li World J. Gastroenterol. 14 2008 4984
23. W. Li, S.-L. Zhang, N. Wang, B.-B. Zhang, and M. Li Cancer Invest. 29 2011 339
24. J.H. Heo, H.N. Seo, Y.J. Choe, S. Kim, C.R. Oh, Y.D. Kim, H. Rhim, D.J. Choo, J. Kim, and J.Y. Lee Bioorg. Med. Chem. Lett. 18 2008 3899
25. S.Y. Jung, S.H. Lee, H.B. Kang, H.A. Park, S.K. Chang, J. Kim, D.J. Choo, C.R. Oh, Y.D. Kim, J.H. Seo, K.-T. Lee, and J.Y. Lee Bioorg. Med. Chem. Lett. 20 2010 6633
26. H.B. Kang, H.K. Rim, J.Y. Park, H.W. Choi, D.L. Choi, J.H. Seo, K.S. Chung, G. Huh, J. Kim, D.J. Choo, K.-T. Lee, and J.Y. Lee Bioorg. Med. Chem. Lett. 22 2012 1198
27. H.K. Rim, H.W. Lee, I.S. Choi, J.Y. Park, H.W. Choi, J.H. Choi, Y.W. Cho, J.Y. Lee, and K.-T. Lee Bioorg. Med. Chem. Lett. 22 2012 7123
28. L.V. Rubinstein, R.H. Shoemaker, K.D. Paull, R.M. Simon, S. Tosini, P. Skehan, D.A. Scudiero, A. Monks, and M.R. Boyd J. Natl. Cancer Inst. 82 1990 1113 The effect of synthetic compound on cell viability was assessed by using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay in 3 replicates. Each cancer cells were seeded and incubated in 96-well, flat-bottomed plates for 24 h and were exposed to various concentrations of test agents dissolved in DMSO (final concentration, 0.1%) for 48 h. Controls received DMSO vehicle at a concentration equal to that in drug-treated cells. The medium was removed, replaced by 200 μL of 0.5 mg/mL MTT in 10% fetal bovine serum containing RPMI, and cells were incubated in the carbon dioxide incubator at 37 C for 2 h. Supernatants were removed from the wells and the reduced MTT dye was solubilized in 100 μL/well DMSO. Absorbance at 540 nm was determined on a plate reader.
29. K.W. Lee, H.J. Kim, Y.S. Lee, H.J. Park, J.W. Choi, J. Ha, and K.-T. Lee Carcinogenesis 2007 1928 28 A2780 cells were treated with various concentrations of KYS05090, and then washed with 1 mL phosphate buffered saline (PBS), fixed in 70% ice-cold ethanol and kept in a freezer overnight. The fixed cells were centrifuged, washed twice with PBS and re-suspended in PBS containing 50 mg/mL PI and 100 μg/mL DNase-free RNase A. The cell suspension, which was hidden from light, was incubated for 30 min and analyzed using the fluorescence- activated cell sorting cater-plus FACS (Becton Dickinson Co., Heidelberg, Germany).
30. J.Y. Park, H.W. Choi, D.L. Choi, S.J. Jang, J.H. Kim, J.H. Lee, D.J. Choo, J. Kim, K.-T. Lee, and J.Y. Lee Bull. Korean Chem. Soc. 34 2013 482
31. H. Huber, G. Huber, and K.O. Stetter Syst. Appl. Microbiol. 6 1985 105 A2780 cells were harvested 24 h post-treatment, washed briefly in PBS, and fixed in 3.7% formaldehyde at 25 C for 10 min. Following fixation, cells were washed three times with PBS and stained with 0.1 μg/mL DAPI (4′,6-diamidine- 2′-phenylindole: Roche) for 5 min. Cells were again washed three times with PBS and mounted on glass slides in PBS containing 10% glycerol. DAPI stained cells were examined by fluorescence microscopy with a ZEISS microscope.
32. K. Jurkat-Rott, and F. Lehmann-Horn J. Physiol. 554 2004 609
33. E. Vázquez, and M.A. Valverde Semin. Cell Dev. Biol. 17 2006 607
34. L. Ge, N.T. Hoa, A.N. Cornforth, D.A. Bota, A. Mai, D.I. Kim, S.K. Chiou, M.J. Hickey, C.A. Kruse, and M.R. Jadus J. Immunol. 189 2012 2625